Jon Congleton Buys Shares of IMUX
Jon Congleton purchased 50,740 shares of IMUX on June 29, 2026.
Key Points
- Jon Congleton bought 50,740 shares of IMUX on June 29, 2026.
- Shares of IMUX traded near $15.30 on Tuesday.
- Analysts from B. Riley Securities and HC Wainwright & Co. maintained buy ratings on IMUX.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jon Congleton, an insider, made a significant move by purchasing 50,740 shares of IMUX on June 29, 2026. This transaction was not part of a pre-arranged trading plan.
Insider Buying and Selling at Immunic, Inc.
Several insiders at IMUX were active on June 29, 2026. Jason Tardio, the President and COO, acquired 253,000 shares, while Glenn Whaley, the CFO, purchased 120,000 shares. Other insiders, including Joerg Neermann and Daniel Vitt, also made substantial purchases of 25,370 and 445,000 shares, respectively. These transactions were direct buys and not part of any planned trading.
Other Institutional Activity in IMUX
Several institutional investors adjusted their positions in IMUX. Aberdeen Group PLC reduced its holdings by 7,419,547 shares, ending with 824,394 shares valued at about $9.15 million. BVF Inc/IL also cut its stake significantly, selling 6,887,675 shares to hold 765,297 shares worth approximately $8.49 million. Avidity Partners Management LP decreased its position by 4,029,470 shares, retaining 669,941 shares valued at roughly $7.44 million. Meanwhile, Vanguard Capital Management LLC and Soleus Capital Management, L.P. opened new positions with 513,832 shares valued at $5.70 million and 450,000 shares worth $4.99 million, respectively.
Immunic, Inc. Stock Up 0.1%
Shares of IMUX traded near $15.30 on Tuesday. The stock has seen varied analyst attention, with B. Riley Securities maintaining a buy rating with a $27 price target as of May 22, 2026. HC Wainwright & Co. also maintained a buy rating, setting a $22 target on April 30, 2026.
$IMUX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 22, 2026, B. Riley Securities maintained its buy rating on IMUX with a price target of $27. HC Wainwright & Co. reiterated its buy rating with a $22 target on April 30, 2026. Stifel initiated coverage with a buy rating and a $2.5 target on April 17, 2026. Guggenheim also started coverage with a buy rating and a $7 target on March 24, 2026.
Bottom Line
Jon Congleton's purchase of IMUX shares is noteworthy, reflecting potential confidence in the company's prospects. While insider buying can signal optimism, it's essential to remember that these transactions are not necessarily indicative of the company's future performance. Investors often track such moves for insight into insider sentiment, but they should consider it as part of a broader investment strategy.
Get Immunic, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMUX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.